<DOC>
	<DOCNO>NCT00075205</DOCNO>
	<brief_summary>This study examine whether Rimonabant , drug block cannabinoid-1 ( CB1 ) receptor brain , affect alcohol consumption . Substances call endocannabinoids , many effect marijuana , bind CB1 receptor . Animal study show CB1 receptor block , animal consume less alcohol . Healthy normal volunteer 21 40 year age consume 20 40 alcoholic drink per week , drink least 4 day week , seek treatment alcoholism may eligible study . Candidates screen medical history , include question alcohol drug use , physical examination , blood urine test , breath alcohol test , electrocardiogram . Participants ask mental health history use alcohol , cigarettes illicit drug , fill questionnaire evaluate emotional state personality . Then , begin baseline evaluation call number NIH Clinical Center 21 day report much alcohol drank day . One week start baseline evaluation , randomly assign take either Rimonabant placebo ( pill active ingredient ) 2 week . Before start drug , urine drug screen measurement blood alcohol level . After 1 week test medication , return Clinical Center monitor drug placebo side effect , , blood alcohol level test , urine drug screen , blood test routine blood chemistry . After 2 week test medication , come Clinical Center noon alcohol self-administration test . Before test , give breath alcohol test urine drug test . The result test must negative continue study . The alcohol self-administration test videotape . A heparin lock place vein participant 's arm . This small needle remain arm duration study avoid multiple needle stick blood draw . Blood drawn periodically test determine routine laboratory value , cotinine level ( assessment smoking status ) , amount Rimonabant placebo body , level various hormone . Thirty minute test begin every 30 minute test , participant complete questionnaire rating scale regard mood desire drink . Five minute test ...</brief_summary>
	<brief_title>Rimonabant Reduce Alcohol Consumption</brief_title>
	<detailed_description>Recent study show endogenous cannabinoids modulate appetitive behavior . For example , antagonist CB1 cannabinoid receptor , SR141716 , decrease food intake animal well human decrease alcohol consumption rodent model voluntary ethanol consumption . In protocol , individual consume 20 40 alcohol drink per week , seek alcohol treatment , recruit community . Following one week baseline evaluation , participant randomize accord double-blind design receive either placebo SR141716 two additional week prior admit hospital participate alcohol self-administration experiment . The design experiment previously show O'Malley et al . ( 1 ) effective paradigm study effect medication alcohol consumption . Following baseline psychological endocrine measure , participant receive prim dose ethanol design raise breath alcohol level ( BAL ) 0.03 g/dl opportunity consume eight drink receive $ 3 dollar drink consume two hour period . It hypothesize participant receive SR141716 , compare receive placebo , decrease alcohol consumption . Following study , participant carefully counsel alcohol consumption provide referral alcohol treatment .</detailed_description>
	<mesh_term>Alcohol Drinking</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Rimonabant</mesh_term>
	<criteria>INCLUSION CRITERIA Male female healthy participant , 21 45 year age . Weight Body Mass Index : Males : 60 kg 90 kg ; Body Mass Index 18 28 . Females : 45 kg 80 kg ; Body Mass Index 18 28 . Certified healthy comprehensive clinical assessment ( detailed medical history complete physical examination ) . Normal vital sign 10 minute supine position : systolic blood pressure 95 mmHg 140 mmHg , diastolic blood pressure 50 mmHg 90 mmHg , heart rate 45 bpm 90 bpm . Normal 12lead EKG , PR le 210 m , QRS le 120 m , QTcB ( 1 ) less equal 430 m male le equal 450 m female ( incomplete right bundle branch block accept ) . Laboratory result within normal range . Laboratory result find marginally outside normal range ( i.e. , minor variance complete blood count ( CBC ) electrolytes ) clinically evaluate relevance protocol . Liver function must less two time normal . Written inform consent prior study participation . Female participant childbearing capability must use double contraceptive method ( oral contraceptive , condom spermicide intrauterine device spermicide ) start study two month post medication trial . Normal dietary habit willingness abstain grapefruit juice consumption study . ( Grapefruit juice inhibits hepatic enzyme could potentially interfere metabolism SR141716 . ) Must agree abstain use illicit drug duration study . EXCLUSION CRITERIA : Any history presence significant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic , hematological , neurologic ( include history convulsion ) , systemic , infectious disease , psychiatric disorder ( i.e. , current diagnosis major depression , panic disorder , eat disorder , history schizophrenia , bipolar disorder , obsessive compulsive disorder ) . Individuals report suicidal ideation past history suicide attempt . Frequent headache and/or migraine , recurrent nausea and/or vomit . Symptomatic hypotension whenever decrease blood pressure asymptomatic postural hypotension define decrease systolic blood pressure ( SBP ) equal great 20 mmHg within two minute change supine stand position . Blood donation within three month administration . Presence history allergy unusual reaction drug anesthetic would suggest participant could problem tolerate SR141716 placebo . A participant , judgment Investigator , likely noncompliant , violent drinking , unable cooperate language problem poor mental development . Participant contact case emergency . Currently take prescription medication overthecounter medication regular basis . Participants allow take occasional pain medication antibiotic , get sick participation protocol . Excessive consumption beverage xanthine base ( great 6 cup glasses/day ) . Female participant positive BetaHCG test ( urine and/or plasma ) lactating . Positive reaction follow test : HBs antigen , antiHCVantibody , antiHIV1 antibody , antiHIV2 antibody . ( Hepatitis could interfere metabolism SR141716 liver . HIV could alter brain function . ) Positive result screen drug abuse ( amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , opiates ) . A DSMIV diagnosis illicit drug dependence last 6 month . Participants come NIAAA Clinic evidence withdrawal symptom result score 8 CIWA Instrument .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2, 2010</verification_date>
	<keyword>Alcohol Consumption</keyword>
	<keyword>Alcohol Treatment</keyword>
	<keyword>Medication Trial</keyword>
	<keyword>Craving</keyword>
	<keyword>Cannabinoids</keyword>
	<keyword>CB 1 Receptor Antagonist</keyword>
	<keyword>SR141716</keyword>
	<keyword>Alcoholism</keyword>
</DOC>